Get the Stockscreener App
22.35
0.54%
0.13
Pharvaris Nv stock is traded at $22.35, with a volume of 216.50K.
It is up +0.54% in the last 24 hours and down -4.49% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$22.22
Open:
$22.12
24h Volume:
216.50K
Relative Volume:
1.16
Market Cap:
$1.43B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-7.9154
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
-2.10%
1M Performance:
-4.49%
6M Performance:
+21.61%
1Y Performance:
-7.49%
1-Day Range:
$21.21
$23.82
1-Week Range:
$21.21
$23.82
52-Week Range:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
22.37 | 1.43B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Full technical analysis of Pharvaris N.V. stockJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Custom watchlist performance reports with Pharvaris N.V.Trade Risk Report & Low Risk High Reward Ideas - newser.com
Can Pharvaris N.V. (9EN) stock deliver strong annual returnsJuly 2025 Market Mood & High Yield Stock Recommendations - newser.com
How sentiment analysis helps forecast Pharvaris N.V.Sell Signal & Community Consensus Trade Alerts - newser.com
Technical signs of recovery in Pharvaris N.V.July 2025 Catalysts & Weekly Chart Analysis and Guides - newser.com
What recovery options are there for Pharvaris N.V.Trade Risk Report & Free Expert Approved Momentum Trade Ideas - newser.com
Is Pharvaris N.V. stock safe for conservative investorsMarket Sentiment Summary & Safe Entry Zone Tips - newser.com
Will Pharvaris N.V. stock attract ESG investorsBuy Signal & Stock Portfolio Risk Management - newser.com
HC Wainwright & Co. Initiates Coverage of Pharvaris N.V. (PHVS) with Buy Recommendation - MSN
Visual analytics tools that track Pharvaris N.V. performanceJuly 2025 Decliners & Low Risk High Reward Ideas - newser.com
How forex fluctuations impact Pharvaris N.V. (9EN) stockAnalyst Upgrade & Free Real-Time Market Sentiment Alerts - newser.com
Is Pharvaris N.V. (9EN) stock undervalued after correctionJuly 2025 Institutional & Growth Focused Entry Reports - newser.com
Can Pharvaris N.V. (9EN) stock reach $200 price targetWeekly Trade Review & Step-by-Step Trade Execution Guides - newser.com
Can Pharvaris N.V. stock deliver sustainable ROEJuly 2025 Price Swings & AI Based Buy and Sell Signals - newser.com
How Pharvaris N.V. stock compares to market leaders2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
Cash per share of Pharvaris N.V. – BER:9EN - TradingView
Will earnings trigger a reversal in Pharvaris N.V.Insider Selling & Low Risk High Win Rate Stock Picks - newser.com
Institutional Investors May Adopt Severe Steps After Pharvaris N.V.'s (NASDAQ:PHVS) Latest 3.4% Drop Adds to a Year Losses - 富途牛牛
Can Pharvaris N.V. stock maintain operating marginsTrade Analysis Report & Weekly Watchlist of Top Performers - fcp.pa.gov.br
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):